The Biomarker Revolution in Medicine and Drug Development

In drug development, biomarkers have revolutionized clinical trial design, enabling researchers to stratify patients, assess drug efficacy earlier, and reduce attrition rates. The emergence of pharmacogenomic biomarkers has allowed for more precise, personalized therapies, reducing adverse effects while improving patient outcomes. Meanwhile, in diagnostics, advances in biomarker science have driven the rise of companion diagnostics, liquid biopsies, and multi-omics approaches, expanding the ability to detect diseases with greater accuracy and at earlier stages.

The journey of biomarkers from rudimentary clinical indicators to sophisticated molecular tools mirrors the broader advances in biomedical science. Over the past 30 years, the field has benefited from breakthroughs in genomics, proteomics, bioinformatics, and artificial intelligence, enabling deeper insights into human biology than ever before. Landmark developments — such as the sequencing of the human genome, the emergence of targeted therapies in oncology, and the integration of artificial intelligence (AI)-driven biomarker discovery — have fundamentally reshaped both research and clinical practice.

The concept of biomarkers predates modern molecular medicine, with early indicators of disease rooted in observable physiological and biochemical changes. Traditional biomarkers in clinical practice, such as glucose levels for diabetes and cholesterol levels for cardiovascular disease, have been fundamental in diagnosing and managing chronic conditions. These markers provided an objective means to assess disease status long before the advent of advanced molecular profiling.¹

The first applications of biomarkers in drug development and clinical trials were similarly based on physiological and biochemical indicators. In the mid-to-late 20th century, pharmacologists relied on serum enzyme levels, blood pressure measurements, and liver function tests to evaluate drug efficacy and toxicity.² The use of histological and serological markers, such as prostate-specific antigen (PSA) for prostate cancer and liver enzyme panels for hepatotoxicity assessment, became critical in identifying treatment responses and safety risks in early-phase clinical trials.³

Despite their utility, these early biomarkers were limited in specificity and predictive power. Most relied on broad physiological readouts rather than underlying molecular mechanisms, making it difficult to distinguish between disease subtypes or predict individual patient responses to treatment.⁴ This limitation became increasingly apparent as the complexity of human biology and disease pathophysiology became better understood.

The 1990s and early 2000s marked a turning point in biomarker science, driven by advances in genomics, proteomics, and computational biology. The completion of the Human Genome Project in 2003 revolutionized drug discovery by enabling the identification of genetic variations associated with disease susceptibility and drug response.⁵ These developments ushered in the era of molecular biomarkers, allowing researchers to move beyond broad biochemical markers toward more precise, mechanistic indicators of disease and treatment response.⁶

One of the most significant breakthroughs of this period was the introduction of pharmacogenomic biomarkers, which linked genetic profiles to drug efficacy and toxicity. A key example is HER2 (human epidermal growth factor receptor 2), which was identified as a predictive biomarker for response to trastuzumab (Herceptin) in breast cancer.⁷ The success of HER2-targeted therapy demonstrated the power of biomarkers in personalizing treatment, leading to the broader adoption of companion diagnostics.⁸

In parallel, proteomic approaches enabled the discovery of protein-based biomarkers, expanding biomarker applications beyond genetics. Proteins such as C-reactive protein (CRP) for inflammation and amyloid-beta for Alzheimer’s disease became widely studied as diagnostic and prognostic tools.⁹ Proteomic advances also facilitated the identification of drug response biomarkers, allowing for more tailored therapeutic interventions.

As biomarker science progressed, regulatory agencies recognized the need for structured pathways to validate and qualify biomarkers for clinical use. The U.S. Food and Drug Administration (FDA) established the Biomarker Qualification Program to provide a framework for assessing biomarkers' reliability and relevance in drug development.¹⁰ This initiative helped standardize biomarker applications in regulatory decision-making and clinical trial designs, fostering greater adoption of biomarker-driven drug development strategies.¹¹

The emergence of molecular biomarkers in the late 20th and early 21st centuries laid the foundation for modern precision medicine, shifting from a one-size-fits-all approach to treatment toward data-driven, patient-specific strategies. With genomics and proteomics expanding the biomarker landscape, researchers were poised to develop even more sophisticated diagnostic and therapeutic tools, setting the stage for the next wave of innovations in biomarker science.

The application of biomarkers in drug discovery has fundamentally transformed how new therapies are identified and validated. Biomarkers aid in target identification and validation, helping researchers pinpoint disease mechanisms and molecular pathways that are most relevant for therapeutic intervention. Genomic and proteomic advances have played a crucial role in this process, enabling the discovery of drug targets based on disease-associated gene expression profiles and protein interactions.¹²

By integrating proteomics and genomics into early-stage drug discovery, researchers can now screen thousands of potential drug candidates against specific biomolecular signatures. This approach has significantly improved the efficiency of drug development, reducing the likelihood of late-stage failures due to unforeseen efficacy or safety issues.² In oncology, for example, the use of next-generation sequencing (NGS) and proteomic profiling has led to the discovery of targeted therapies for genetically defined patient subpopulations, such as BRAF inhibitors for melanoma.⁵

Beyond target identification, biomarkers also play a crucial role in predicting drug toxicity and efficacy. Safety biomarkers can identify potential adverse effects before a drug reaches clinical trials, reducing risks for participants and increasing the likelihood of regulatory approval.¹⁰ For example, cardiac safety biomarkers like troponins and NT-proBNP are routinely used to evaluate potential cardiotoxicity of new drug candidates.¹¹ Meanwhile, efficacy biomarkers allow researchers to measure therapeutic responses early, ensuring that only the most promising drug candidates advance through development.¹³

Biomarkers have revolutionized clinical trial design, enabling more precise patient selection and improving trial outcomes. They are broadly classified into predictive and prognostic biomarkers. Predictive biomarkers help identify patients who are most likely to respond to a specific treatment, while prognostic biomarkers provide information on disease progression regardless of treatment.⁴ For example, EGFR mutations in non-small cell lung cancer serve as a predictive biomarker for response to tyrosine kinase inhibitors.⁶

Several successful biomarker-driven drug approvals have demonstrated the power of personalized medicine. One of the most well-known examples is trastuzumab (Herceptin) for HER2⁺ breast cancer, where HER2 overexpression predicts patient response to therapy.⁷ Similarly, PD-L1 expression levels guide the use of immune checkpoint inhibitors, such as pembrolizumab, in cancer treatment.⁸ These examples highlight how biomarkers can accelerate drug approval timelines by demonstrating clear therapeutic benefit in biomarker-defined patient populations.⁹

Biomarkers have also enabled adaptive trial designs, allowing researchers to modify clinical protocols in real time based on interim biomarker results.⁵ This flexibility has streamlined patient recruitment and stratification, leading to more efficient trials with improved statistical power. For example, the I-SPY 2 trial in breast cancer used biomarker-guided stratification to rapidly assess multiple investigational therapies in parallel, significantly reducing time and cost compared to traditional trial designs.¹³

Despite their advantages, biomarker adoption in drug development is not without challenges, particularly in terms of regulatory approval and standardization. Both the FDA and the European Medicines Agency (EMA) have developed frameworks for biomarker validation, requiring rigorous evidence of analytical validity, clinical validity, and clinical utility.¹⁰ However, regulatory pathways for biomarker qualification remain complex, often requiring longitudinal studies and extensive validation cohorts to gain full regulatory endorsement.¹¹

A key concept in biomarker regulation is context of use (COU), which defines the specific application and intended purpose of a biomarker in drug development.⁴ Establishing COU is crucial for regulatory acceptance, as different applications — such as using a biomarker for patient selection versus monitoring disease progression — may require distinct levels of validation and supporting data.³

Challenges in reproducibility, standardization, and regulatory alignment further complicate biomarker adoption. Many biomarkers lack standardized assays, leading to variability in test results across different laboratories and clinical settings.¹⁴ Additionally, multi-omics and AI-driven biomarker discovery introduce new complexities in validation, requiring regulatory bodies to adapt their evaluation frameworks to accommodate evolving technologies.⁶

Despite these hurdles, regulatory agencies and industry stakeholders continue to work toward harmonizing biomarker qualification pathways, ensuring that these critical tools can be reliably integrated into drug development and clinical practice. The increasing collaboration between regulatory agencies, academic institutions, and biopharma companies is helping to address these challenges, paving the way for the next generation of biomarker-driven drug development.⁹

The shift from broad-spectrum treatments to targeted therapies represents one of the most significant transformations in modern medicine. Traditional treatment approaches often relied on one-size-fits-all regimens, which could result in variable efficacy and unwanted side effects. The integration of biomarkers in diagnostics has allowed for personalized medicine, where therapies are tailored to patients based on their molecular profiles.¹

A key component of this transformation has been the development of companion diagnostics — diagnostic tests designed to identify patients who are most likely to benefit from a particular therapy. These tests have become critical in oncology, neurology, and immunology, where biomarker-driven therapies offer higher efficacy and reduced toxicity.²

Case Studies of Biomarker-Driven Therapies

• PD-L1 inhibitors: In cancer immunotherapy, PD-L1 expression levels are used to determine patient eligibility for immune checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo). High PD-L1 expression correlates with better responses to these therapies, improving patient outcomes.⁷

• ALK inhibitors: The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements has led to the development of targeted therapies like crizotinib and alectinib, significantly improving survival rates in ALK-positive non-small cell lung cancer patients.⁸

• HER2 testing for breast cancer: The success of trastuzumab (Herceptin) in HER2⁺ breast cancer remains one of the most well-known examples of a biomarker-guided therapy, demonstrating how diagnostics can drive treatment selection and improve patient outcomes.⁴

As the reliance on biomarkers in treatment decisions grows, regulatory agencies have developed frameworks to ensure the safety, accuracy, and clinical validity of companion diagnostics. The FDA’s Companion Diagnostics Guidance outlines requirements for co-development of therapeutics and their associated biomarker-based tests.¹⁰ However, challenges remain in standardizing biomarker assays across different testing platforms and ensuring global regulatory alignment.¹¹

While genomic and proteomic biomarkers have dominated precision medicine, emerging technologies are pushing biomarker science beyond traditional molecular indicators.

AI and machine learning (ML) have accelerated biomarker discovery by analyzing vast biological data sets and identifying novel disease markers that might not be apparent through conventional research methods. Deep learning algorithms can integrate data from genomic, proteomic, and imaging sources, enhancing diagnostic accuracy and disease prediction.⁹ AI-driven biomarker analysis has been particularly transformative in radiomics, where imaging biomarkers can detect early cancer lesions with unprecedented precision.⁶

Traditional single-marker diagnostics are giving way to multi-omics approaches, which integrate data from:

• Genomics (DNA mutations, copy number variations)

• Proteomics (protein expression, post-translational modifications)

• Metabolomics (small molecule metabolites linked to disease states)

For instance, in neurodegenerative diseases, combining genomic risk factors (APOE4 mutations) with proteomic markers (tau, amyloid-beta) and metabolomic profiles has enhanced the early detection of Alzheimer’s disease.³

The rise of wearable devices and mobile health technologies has led to the emergence of digital biomarkers, which provide real-time physiological and behavioral data. These biomarkers enable continuous patient monitoring, particularly for chronic conditions like cardiovascular disease and diabetes.¹⁴. Examples include:

• Heart rate variability as a biomarker for cardiac health

• Continuous glucose monitoring (CGM) in diabetes management

• Speech and movement analysis for early Parkinson’s disease detection

While digital biomarkers hold promise for remote patient monitoring and early disease detection, standardization and regulatory oversight remain key challenges in their widespread adoption.¹³

As biomarker-based diagnostics continue to evolve, several challenges and ethical concerns must be addressed to ensure equitable and effective implementation.

With the growing use of genomic, proteomic, and digital biomarkers, protecting patient data privacy is becoming increasingly complex. The integration of AI-driven biomarker platforms raises concerns over data breaches, misuse of genetic information, and consent in large-scale biomarker studies.⁴ Regulatory frameworks, such as GDPR (General Data Protection Regulation) and HIPAA (Health Insurance Portability and Accountability Act), aim to safeguard biomarker data, but global harmonization of privacy laws remains a challenge.¹⁰

Most biomarker discovery studies have been conducted in populations of European ancestry, leading to gaps in biomarker applicability across diverse ethnic groups.⁸ This bias can result in reduced accuracy of biomarker-based diagnostics and treatment disparities. For example, certain polygenic risk scores for cancer and cardiovascular disease may not translate well to non-European populations, necessitating more diverse clinical trials and biomarker validation studies.⁶

While biomarker-based diagnostics have improved precision medicine, cost and accessibility remain major barriers in low- and middle-income countries (LMICs). Many companion diagnostics require advanced sequencing technologies, which are expensive and not widely available in resource-limited settings.¹⁴ Addressing these disparities requires:

• Development of low-cost, point-of-care biomarker tests

• Policy initiatives to subsidize biomarker-based diagnostics

• Global collaborations to enhance biomarker accessibility in underserved regions

Despite these challenges, the continued advancement of biomarkers in diagnostics holds immense potential for improving patient outcomes, reducing healthcare costs, and enabling truly personalized medicine on a global scale.

The next frontier of biomarker science is defined by the rapid evolution of non-invasive, real-time, and systems-level biomarkers that promise to transform disease detection and monitoring. Advances in molecular biology, digital health, and bioinformatics are expanding biomarker capabilities beyond traditional blood-based assays to continuous monitoring and individualized diagnostics.

Liquid biopsy represents one of the most promising developments in biomarker science, allowing for non-invasive disease detection and monitoring. By analyzing circulating tumor DNA (ctDNA), exosomes, and circulating RNA, liquid biopsies provide a real-time snapshot of disease progression without the need for invasive tissue sampling.⁶ These approaches are particularly impactful in oncology, where they allow for earlier detection of cancers, monitoring of minimal residual disease, and real-time tracking of tumor evolution.⁷

Beyond oncology, liquid biopsy is being explored for neurodegenerative diseases, where biomarkers such as tau and amyloid-beta in cerebrospinal fluid and plasma are showing promise for early Alzheimer’s disease detection.¹⁴ These advancements pave the way for pre-symptomatic diagnosis and targeted interventions.

The integration of wearable sensors and mobile health applications is revolutionizing how biomarkers are monitored. Continuous glucose monitors (CGMs) for diabetes, ECG sensors for cardiac health, and smartwatch-based biometrics for stress and sleep analysis demonstrate the power of real-time digital biomarkers in chronic disease management.⁹

AI and ML algorithms are enhancing the interpretation of wearable biomarker data, allowing for early detection of irregular heart rhythms, metabolic changes, and neurocognitive decline. Future developments in implantable biosensors may allow for continuous measurement of blood biomarkers such as inflammatory cytokines, oxidative stress markers, and metabolic metabolites.⁸

The human microbiome — the collection of microorganisms residing in the gut, skin, and other body sites — is emerging as a new frontier in biomarker discovery. Studies have shown that gut microbiota composition is linked to a range of diseases, including obesity, inflammatory bowel disease, cancer, and neurodegenerative disorders.⁴

Researchers are developing microbiome-based biomarkers to guide treatment decisions in fields such as oncology (immunotherapy response prediction), gastroenterology (microbial signatures in irritable bowel disease and colorectal cancer), and psychiatry (gut–brain axis influence on mental health).³ As sequencing technologies and AI-driven microbiome analytics improve, these biomarkers could redefine how we diagnose and treat disease.

Despite the growing promise of biomarkers, widespread clinical adoption faces significant hurdles in terms of standardization, regulatory harmonization, and global implementation.

Biomarker-based diagnostics and therapeutics require rigorous validation to ensure reproducibility and clinical utility. However, regulatory agencies such as the FDA, EMA, and PMDA have differing standards for biomarker qualification, making global adoption challenging.10 Harmonizing biomarker validation requirements will be crucial for expanding the impact of biomarker-based medicine across diverse healthcare systems.¹¹

A more collaborative approach among researchers, pharmaceutical companies, and regulatory bodies is needed to accelerate biomarker qualification and translation. Programs such as the FDA’s Biomarker Qualification Program and international collaborations like the Biomarkers Consortium have already made strides in this direction, but greater data sharing and public-private partnerships will be essential for long-term progress.¹³

As biomarker science becomes increasingly multi-omics and AI-driven, the need for large, diverse, and well-curated biomarker databases is more pressing than ever. Initiatives such as the Human Biomarker Reference Database (HBRD) and The Cancer Genome Atlas (TCGA) are enabling more comprehensive biomarker discovery efforts, but further investment in open-access biomarker repositories is needed to ensure global research accessibility.⁹

Over the past 30 years, biomarker science has transformed medicine, enabling earlier disease detection, personalized treatments, and more efficient drug development. The integration of genomics, proteomics, and AI-driven analytics has brought biomarker applications to the forefront of modern healthcare.

• The shift from broad-spectrum treatments to biomarker-guided precision medicine

• The rise of companion diagnostics, enabling targeted therapies in oncology, cardiology, and immunology

• The emergence of liquid biopsies and non-invasive biomarker detection technologies

• The integration of AI, digital biomarkers, and multi-omics approaches

As we look to the future, biomarkers will continue to drive innovation across multiple areas of medicine. The next decade will likely see:

• The expansion of real-time monitoring technologies, enabling earlier disease intervention

• The globalization of biomarker-driven drug development, improving treatment access worldwide

• The rise of microbiome-based diagnostics, redefining how we approach chronic and infectious diseases

Biomarkers have moved from simple clinical indicators to complex, AI-powered diagnostic tools that are reshaping how we detect, treat, and monitor disease. With continued investment, regulatory alignment, and technological innovation, biomarker science will play an even more critical role in advancing precision medicine, improving patient outcomes, and transforming global healthcare for decades to come.

Our parent company, That’s Nice, is committed to supporting the companies and innovators driving the next wave of pharma and biotech innovation. To celebrate That’s Nice’s 30th anniversary, Pharma’s Almanac is diving into 30 groundbreaking advancements, trends, and breakthroughs that have shaped the life sciences, highlighting the industry-defining milestones our agency has had the pleasure of growing alongside. Here’s to 30 years of innovation and the future ahead!

1. Califf, Robert M. “Biomarker definitions and their applications.” Exp. Biol. Med. (Maywood). 6: 213–221 (2018).

2. Gromova, Mariya, et al. “Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.” Biomark. Insights. 15: 1177271920974652 (2020).

3. Pletcher, Mark J and Michael Pignone. “Evaluating the Clinical Utility of a Biomarker.” Circulation. 123: 1116–1124 (2012).

4. Garcia, Laura Patricia Orellana, et al. “Biomarker and Companion Diagnostics — A Review of Medicinal Products Approved by the European Medicines Agency.” Front. Med. Sec. Regulatory Science. 31 Oct. 2021.

5. Hendrikse, Natalie M, et al. “Biomarkers in Medicines Development — From Discovery to Regulatory Qualification and Beyond.” Front. Med. Sec. Regulatory Science. 25 Apr. 2022.

6. Zhou, Yue et al. “Tumor biomarkers for diagnosis, prognosis and targeted therapy.” Signal Transduction and Targeted Therapy. 9:132 (2024).

7. Chan, Yau-Tuen, et al. “Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.” Molecular Cancer. 23: 189 (2024).

8. Bodaghi, Ali, Nadia Fattahi, and Ali Ramazani. “Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.” Heliyon. 9: e13323 (2023).

9. Selvaraj, Prasad Lakshmanan. “Beyond ELISA: the future of biomarker validation.” Drug Target Review. 27 Nov. 2024

10. McCune, Susan. “How biomarkers can improve the drug development process.” U.S. Food and Drug Administration. Accessed 8 Mar. 2025.

11. Hassanein, Mohamed, et al. “Drug Development Through the Prism of Biomarkers: Current State and Future Outlook.” AAPS Newsmagazine. Apr. 2023.

12. Chen, Daohong. “Biomarkers navigate drug development: Pharmacology, effectiveness and safety.” Medicine in Drug Discovery. 21: 100174 (2024) 2024

13. “Biomarkers in drug discovery and development.” European Pharmaceutical Review. 1 Nov. 2010.

14. Das, Sreyashi, et al. “Biomarkers in Cancer Detection, Diagnosis, and Prognosis.” Sensors. 24: 37 (2024).